AtaiBeckley Gains Buy Ratings with $11–$16 Targets and 2026 Phase II Catalysts
Analysts have maintained Buy ratings on AtaiBeckley, with H.C. Wainwright setting a $15 price target on January 28, Guggenheim initiating coverage at $11 on January 20, and JonesTrading reaffirming a Buy at $16 on January 16. Full ownership of BPL-003 after merging with Beckley Psytech and anticipated pivotal Phase II data from three clinical programs in 2026 position the lead compounds for rapid adoption.
1. Analyst Rating Updates
H.C. Wainwright maintained a Buy rating on January 28, assigning a $15 price target. Guggenheim initiated coverage at a Buy with an $11 target on January 20, while JonesTrading reaffirmed its Buy stance on January 16 and set a $16 target, highlighting the company’s advancing clinical pipeline and market opportunity.
2. Strategic Merger Impact
The January merger with Beckley Psytech granted AtaiBeckley full ownership of BPL-003, its lead asset. Early Phase IIIb data showed compelling efficacy and durability in treatment-resistant depression, bolstering prospects for rapid clinical adoption and commercial scaling.
3. Upcoming Clinical Catalysts
AtaiBeckley is positioned for a data-rich 2026, with pivotal Phase II results expected from all three clinical programs. The anticipated readouts, combined with short-duration compounds like BPL-003 and VLS-01, could significantly de-risk the story and support a clinic-based treatment model similar to esketamine.